Loading...
XTSE
PRM
Market cap13mUSD
Jul 09, Last price  
14.70CAD
1D
0.00%
1Q
6.14%
IPO
1.38%
Name

Big Pharma Split Corp

Chart & Performance

D1W1MN
XTSE:PRM chart
P/E
P/S
EPS
3.37
Div Yield, %
8.42%
Shrs. gr., 5y
4.23%
Rev. gr., 5y
-13.95%
Revenues
1m
-21.38%
407,1113,232,0972,434,1403,080,9425,359,3683,926,088311,7641,849,0491,453,670
Net income
4m
P
323,2212,780,0802,579,869265,4234,853,6373,145,517-139,680-538,6244,400,516
CFO
-1m
L-18.56%
-30,954,2591,270,6748,679,1984,348,424-9,000,3591,128,42911,858,414-1,295,523-1,055,016
Dividend
Dec 31, 20250.1031 CAD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Big Pharma Split Corp, a closed-end equity investment fund, was established on September 15, 2017, and maintains its domicile in Canada. Overseen by Harvest Portfolios Group Inc., the fund concentrates its investments primarily within the pharmaceutical sector, targeting publicly traded companies across the United States.
IPO date
Nov 23, 2017
Employees
Domiciled in
CA
Incorporated in
CA

Valuation

Title
in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT